Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALK | Q9UM73 | 14/20 | 0.35 |
| ▸ | INSR | P06213 | 1/20 | 0.35 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | CCR1 | P32246 | 2/20 | 0.33 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.33 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.33 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.33 |
| ▸ | EGFR | P00533 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11900623 | 0.86 | ALK (0.34) | ALKINSRLRRK2CCR1 | |
| SCHEMBL15206515 | 0.70 | ALK (0.63) | ALKINSRLRRK2MAPK8MAPK9 | |
| SCHEMBL18338692 | 0.69 | ALK (0.38) | ALKINSRLRRK2MAPK8MAPK9 | |
| SCHEMBL21715308 | 0.65 | ALK (0.60) | ALKINSRLRRK2MAPK8MAPK9 | |
| SCHEMBL1493718 | 0.64 | ALDH1A1 (0.42) | — | |
| SCHEMBL1493537 | 0.64 | ALK (0.63) | ALKINSRLRRK2 | |
| SCHEMBL29015781 | 0.62 | ALK (0.47) | ALKINSRLRRK2MAPK8MAPK9 | |
| SCHEMBL1376839 | 0.61 | ZAP70 (0.47) | ALKINSRLRRK2MAPK8MAPK9 | |
| SCHEMBL22494174 | 0.60 | INSR (0.44) | ALKINSR | |
| SCHEMBL11901070 | 0.60 | ALK (0.59) | ALKINSRLRRK2MAPK8MAPK9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9012462-B2 | Phosphorous derivatives as kinase inhibitors | ARIAD PHARMACEUTICALS, INC. (US) | 2015-04-21 | — | — | US | disclosed |
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | ARIAD PHARMACEUTICALS, INC. (US) | 2012-08-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120202776-A1 | PHOSPHORUS DERIVATIVES AS KINASE INHIBITORS | PHKA1, PIK3CA, PHKA2 | ALK 370/4885INSR 751/4885LRRK2 1090/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.